quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:35:00·10d
PRRelease
Genmab A/S logo

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer

GMAB· Genmab A/S
Health Care
Original source

Companies

  • GMAB
    Genmab A/S
    Health Care

Recent analyst ratings

  • Apr 22UpdateGoldman-
  • Mar 27UpdateWolfe Research$32.00
  • Mar 2UpdateWells Fargo$40.00
  • Feb 17UpdateJefferies$41.50
  • Feb 17UpdateMorgan Stanley$34.00
  • Sep 23UpdateGuggenheim$43.00

Related

  • ANALYST1d
    Genmab upgraded by Goldman
  • SEC6d
    SEC Form 6-K filed by Genmab A/S
  • SEC6d
    SEC Form 6-K filed by Genmab A/S
  • SEC9d
    SEC Form 6-K filed by Genmab A/S
  • PR9d
    Major Shareholder Announcement
  • SEC9d
    SEC Form 6-K filed by Genmab A/S
  • PR9d
    Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
  • SEC22d
    SEC Form 6-K filed by Genmab A/S
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022